Clinical TrialJun 11, 2026, 07:41 AM
Silence Therapeutics Divesiran Phase 1 Data Shows Durable Efficacy in PV
AI Summary
Silence Therapeutics plc presented follow-up and quality-of-life data from its Phase 1 SANRECO study of divesiran, a siRNA therapy for polycythemia vera (PV), at the EHA 2026 Annual Congress. The data demonstrated durable efficacy, showing substantial and persistent reductions in phlebotomy use, as well as potential improvements in PV symptoms and patient quality-of-life. Divesiran was well tolerated with no serious adverse events. The company anticipates topline results from its ongoing Phase 2 SANRECO study in August 2026, which is evaluating less frequent dosing regimens.
Key Highlights
- Divesiran Phase 1 SANRECO study data presented at EHA 2026 for polycythemia vera (PV).
- Data showed improvements in PV-related symptoms and quality-of-life.
- Substantial reductions in phlebotomy use persisted well beyond the final dose.
- Only 5 phlebotomies required during active treatment period, compared to 80 prior to treatment.
- Only 4 phlebotomies reported during the 16-week follow-up period after the final dose.
- Median time to first phlebotomy was 287 days for 14 patients with further follow-up data.
- Divesiran was well tolerated with no dose-limiting toxicities or treatment-related serious adverse events.
- Topline results for the Phase 2 SANRECO study are expected in August 2026.
Price Impact
More from SLN